Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone metastasis in china.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborator: Novartis
• Treatments: Diphosphonates

Criteria

Inclusion Criteria:

1. Age >18, either sex

2. Histologically confirmed non-small cell cancer

3. One bone metastasis at least confirmed by image(X ray,CT or others)

4. Without receiving zoledronic acid

5. Life expectancy > 6 M

6. ECOG <= 2

7. Signed ICF

Exclusion Criteria:

1. Women who are pregnant or in lactation

2. Patients with hyperostosis

3. with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled

4. Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy

5. Severe co-morbidity of any type that may interfere with assessment of the patient for the study -